A major new report published by the U.K. MS Trust has determined that the country’s National Health Services (NHS) programs relied on by people living with multiple sclerosis (MS) are facing increasing pressures that could lead to inequities in care. Evidence from the Letchworth Garden City, Hertfordshire based MS Trust’s…
research
In a new study entitled “Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis,” a team of researchers performed a comparative analysis of metabolites between control mice and a mouse model with experimental autoimmune encephalitis (EAE, the most commonly used…
In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (Gilenya, Novartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that…
The National Multiple Sclerosis Society has dedicated over $21 million to fund 78 new multiple sclerosis (MS) research studies as part of a broad research plan designed to address MS, re-establish lost functioning caused by the disease in patients, and ultimately end the disease forever. This recent round of investment into MS research is…
A smartphone platform may eventually enable large-scale studies of patients with multiple sclerosis (MS) or other neurologic diseases, according to the findings of a recent study published in the journal Neurology, Neuroimmunology & Neuroinflammation. Smartphones, highly portable and popular, provide a significant opportunity to incorporate information across…
In a recent study entitled “MicroRNA expression profiling of human blood monocyte subsets highlights functional differences,” a team of researchers discovered a pool of 66 microRNAs that underlie differences in phenotype and function of a group of immune cells with key roles in multiple sclerosis. The study was published…
Findings from a recent study published in the Journal of Neurologic Physical Therapy showed that standard approaches to evaluating muscular strength and cardiorespiratory fitness among patients with multiple sclerosis (MS) might be underestimating the patients’ capacities, encouraging clinicians to prescribe less effective exercises. In the study entitled “…
In a recent study published in the journal Immunity, researchers at the Weizmann Institute of Science in Israel reported the findings that a small subtype of immune dendritic cells plays a role in the prevention of both metabolic syndrome and autoimmunity. The study is entitled “…
In a new study entitled “Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation,” a team of scientists discovered the mechanism by which autoreactive T cells are capable of penetrating a patient’s brain and induce multiple sclerosis. The study was recently published in the advance online issue…
Psychiatric comorbidity is common in patients with multiple sclerosis (MS), and affects the MS community more frequently than a matched control population, although the incidence is stable over time, according to recent findings of a study published in the journal Neurology, the Official Journal of the American Academy…
Helius Medical Technologies, Inc., a company dedicated to neurological wellness, recently announced that the multiple sclerosis (MS) pilot study assessing the company’s investigational Portable Neuromodulation Stimulator (PoNS™) device has met all of the study’s goals. PoNS is a non-invasive device that allows the delivery of neurostimulation through the…
A collective team of physician-researchers comprising Dr. Peter Calabresi from Johns Hopkins School of Medicine in Baltimore, Dr. Laura Balcer from NYU Langone Medical Center, and Dr. Elliot Frohman from University of Texas Southwestern School of Medicine are the winners of the 2015 Barancik Prize for Innovation…
New research at the University of Adelaide, Australia, may help pave the way toward the potential inhibition of multiple sclerosis (MS) and other autoimmune diseases. The study entitled “CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells” was published in the journal …
In a new article published in the journal Trends in Biotechnology, Korean researchers suggest that diseases of the central nervous system (CNS) might be better studied using compact, accessible chip technology than in current methods. The report, titled “Central Nervous System and its Disease…
In a recent study published in the journal BMJ Open, a research team explored the use of fatigue management strategies in patients with multiple sclerosis (MS) who attended a group-based fatigue management program. The Multiple Sclerosis Council for Clinical Practice Guidelines defines fatigue as “a subjective lack…
In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosis (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…
A recent study published in the journal Science Translational Medicine provided new insights into the role of B cells in multiple sclerosis (MS), and points to a specific line of possible new therapies. The study is entitled “Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell…
A new study from Sweden indicates that vitamin D could help protect nerve cells (neurons) in multiple sclerosis (MS). The report, titled “Vitamin D and axonal injury in multiple sclerosis,“ was published on October 13, 2015, in the Multiple Sclerosis Journal. Scientists have demonstrated, in…
Results from a recent study published in the journal Immunity indicate that dietary fat has an influence in the duration and severity of autoimmune flare-ups in a mouse model of multiple sclerosis. The team of researchers also showed that adjusting the length of the fatty acids consumed by…
In a recent study published in the International Journal of MS Care, a team of researchers determined that among patients with multiple sclerosis (MS), fatigue was the most common symptom associated with the decision to leave work or reduce the employment status. According to the researchers, comprehensive…
In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…
A recently published study in the journal PLOS One reported a new tool to assess risk knowledge in multiple sclerosis (MS) patients. The study was conducted by an international team led by researchers at the University Medical Center Eppendorf in Hamburg, Germany, and is entitled “…
A new study published in the Journal of Biological Chemistry revealed novel potential inhibitors of specific proteins involved in the pathogenesis of cancer and autoimmune disorders, like multiple sclerosis. The study is entitled “Dual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel…
Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the company’s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…
Among the different therapeutic approaches being explored for treating MS, adult stem cell therapy continues to be one of the most discussed and anticipated in the MS community. “Stem cells” — the common term for undifferentiated, self-renewing proliferating cells — are currently being investigated for their ability to treat patients in a wide range of disease…
Researchers from the Gladstone Institutes have shown in a new study that fibrinogen, an important blood coagulation protein, can induce an autoimmune response in the central nervous system when the blood-brain barrier (BBB) is disrupted and blood proteins enter the brain. The study, entitled “Blood coagulation protein fibrinogen promotes…
A recent study of people with relapsing remitting multiple sclerosis (RRMS) found that high-dose oral vitamin D3 supplementation did not influence markers of inflammation. Inflammation is a reaction to bodily injury that may be over-activated in people with multiple sclerosis (MS). The article, titled “Vitamin D supplementation and systemic inflammation in…
A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…
Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 – 10, 2015). The first parallel session was entitled “Will…
Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 – 10, 2015). The first parallel session was entitled “Will MS…
Recommended Posts
- Bladder problems in MS may lower quality of life by fueling loneliness
- MS can change your identity, but what about your personality?
- Dosing begins in trial testing treatment for MS, obesity
- MS patients value empathy as a top priority in their healthcare
- Teenage bout of mono may serve as a big red flag for MS risk later